The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy | Citedby Results | Cancer Research Communications | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy

Cancer Research Communications (2021) 1 (3): 164–177.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Human Non-Small Cell Lung Cancer-Chicken Embryo Chorioallantoic Membrane Tumor Models for Experimental Cancer Treatments

Jing Li
Tereza Brachtlova
Ida H. van der Meulen-Muileman
Stijn Kleerebezem
Chang Liu
Peiyu Li
Victor W. van Beusechem

International Journal of Molecular Sciences (2023) 24 (20): 15425.

The role of EphA2 in ADAM17- and ionizing radiation-enhanced lung cancer cell migration

Verena Waller
Fabienne Tschanz
Rona Winkler
Martin Pruschy

Frontiers in Oncology (2023) 13

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis

Eva Romanovsky
Klaus Kluck
Iordanis Ourailidis
Michael Menzel
Susanne Beck
Markus Ball
Daniel Kazdal
Petros Christopoulos
Peter Schirmacher
Thorsten Stiewe
Albrecht Stenzinger
Jan Budczies

Cell Death Discovery (2023) 9 (1)

Genetic Predisposition to Elevated Levels of Circulating ADAM17 Is Associated with the Risk of Severe COVID-19

Mengyu Pan
Isabel Goncalves
Andreas Edsfeldt
Jiangming Sun
Per Swärd

International Journal of Molecular Sciences (2023) 24 (21): 15879.

Immunomodulatory role of metalloproteinase ADAM17 in tumor development

Kai Wang
Zixue Xuan
Xiaoyan Liu
Meiling Zheng
Chao Yang
Haiyong Wang

Frontiers in Immunology (2022) 13